InBody Co.,Ltd (KOSDAQ:041830)
 28,650
 +1,700 (6.31%)
  Oct 31, 2025, 3:30 PM KST
InBody Co.,Ltd Revenue
InBody Co.,Ltd had revenue of 56.17B KRW in the quarter ending June 30, 2025, with 11.80% growth. This brings the company's revenue in the last twelve months to 217.55B, up 17.38% year-over-year. In the year 2024, InBody Co.,Ltd had annual revenue of 204.46B with 20.03% growth.
Revenue (ttm) 
 217.55B
Revenue Growth 
 +17.38%
P/S Ratio 
 1.51
Revenue / Employee 
 636.10M
Employees 
 342
Market Cap 
328.58B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 204.46B | 34.11B | 20.03% | 
| Dec 31, 2023 | 170.35B | 10.35B | 6.47% | 
| Dec 31, 2022 | 160.00B | 22.17B | 16.08% | 
| Dec 31, 2021 | 137.84B | 30.71B | 28.67% | 
| Dec 31, 2020 | 107.12B | -9.94B | -8.49% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| Samsung Biologics | 5.03T | 
| Celltrion | 3.75T | 
| Yuhan | 2.17T | 
| SK Biopharmaceuticals | 620.28B | 
| PharmaResearch | 449.81B | 
| Sam Chun Dang Pharm. | 215.10B | 
| ALTEOGEN | 158.06B | 
| LigaChem Biosciences | 148.28B |